CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
VM202biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02039401
NCT02039401Phase 2Completed
CompareCT.gov

A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis

Helixmith Co., Ltd.·interventional·Posted Jan 17, 2014·Updated Oct 6, 2025

In Brief

A Phase 2 clinical trial evaluating VM202 for Amyotrophic Lateral Sclerosis. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and tolerability of intramuscular injections of VM202 at different injection sites in people with amyotrophic lateral sclerosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 17, 2014
Enrollment StartMar 11, 2014
Primary CompletionAug 3, 2015
Study CompletionMar 6, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.5 years ago

Interventions

VM202biological